In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial

Session Poster Session 5

Speaker Lars Wallentin

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session
  • FP Number : P4797

Authors : A Siegbahn (Uppsala,SE), Z Hijazi (Uppsala,SE), J Lindback (Uppsala,SE), J Oldgren (Uppsala,SE), T Pol (Uppsala,SE), JH Alexander (Durham,US), RD Lopes (Durham,US), CB Granger (Durham,US), L Wallentin (Uppsala,SE)


A. Siegbahn1 , Z. Hijazi2 , J. Lindback3 , J. Oldgren2 , T. Pol2 , J.H. Alexander4 , R.D. Lopes4 , C.B. Granger4 , L. Wallentin2 , 1Uppsala University, Department of Medical Sciences, Clinical Chemistry, and Uppsala Clinical Research Center, UCR - Uppsala - Sweden , 2Uppsala University, Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, UCR - Uppsala - Sweden , 3Uppsala University, UCR-Uppsala Clinical Research Center - Uppsala - Sweden , 4Duke Clinical Research Institute - Durham - United States of America ,

On behalf: the ARISTOTLE investigators

European Heart Journal ( 2018 ) 39 ( Supplement ), 1007

Background: Treatment of patients with atrial fibrillation (AF) with oral anticoagulants is essential to prevent thromboembolic events, mainly stroke, and mortality. However, this therapy is also associated with significant risk of major bleeding events. Biomarkers have recently been recognized to provide improved risk prediction models in AF populations.

Purpose: To further improve the assessment of bleeding risk and understand the pathophysiological mechanisms for bleeding events in patients with AF. The multiplex analytical technology Proximity Extension Assay (PEA) was utilized to screen hundreds of plasma biomarkers simultaneously in small amounts of plasma.

Method: In an unstratified case-control cohort of the ARISTOTLE trial a total of 204 cases with ISTH major bleeding were identified and a random sample of 3,996 controls were followed for a median of 1.7 years. Plasma samples obtained at randomization were analysed by conventional immunoassays or using PEA panels for cardiovascular disease and inflammation, which measured 255 protein biomarkers in multiplex. The association of biomarkers and outcome was evaluated simultaneously by Random Forest and individually by Cox-regression analyses adjusted for clinical characteristics and renal function. The significance level was adjusted for multiple testing.

Results: Six biomarkers were identified as most strongly associated with major bleeding according to both Random Forest and the adjusted Cox-regression analyses. The hazard ratio (95% confidence intervals) per interquartile range was 1.18 (1.04–1.33) for Ephrin type-B receptor 4 (EPHB4), 1.31 (1.14–1.52) for Fibroblast growth factor 23 (FGF-23), 1.35 (1.09–1.68) for Growth differentiation factor 15 (GDF-15), 1.55 (1.27–1.90) for Osteopontin (OPN), 1.45 (1.12–1.87) for Tumor necrosis factor receptor 1 (TNF-R1), 1.36 (1.15–1.60) for Trefoil factor 3 (TFF3).

Conclusions: In patients with AF treated with oral anticoagulants, out of a large number of biomarkers, Osteopontin and Fibroblast growth factor 23 were the strongest predictors of major bleeding events. The association of these biomarkers with bleeding events in this setting is novel and the pathophysiological mechanisms behind these findings warrant validation and further in-depth studies.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are